Apollomics, a Bay Area-Hangzhou biopharma, started a China Phase I trial of uproleselan in patients with relapsed or refractory acute myeloid leukemia (AML). In 2020, Apollomics acquired China rights to uproleselan from GlycoMimetics in a two-drug, $189 million deal. Both drugs are novel E-selectin-based immunotherapies aimed at leukemia. Uproleselan is designed to block E-selectin from binding with blood cancer cells, which causes drug resistance. It will be administered along with chemotherapy. Apollomics was incubated by OrbiMed Asia to develop cancer immunotherapies. More details.... Stock Symbol: (NSDQ: GLYC) Share this with colleagues: // //